ADCT Adc Therapeutics SA

  1. Stocks
  2. Healthcare
  3. NYSE: ADCT

Price (delayed)

$1.305

Market cap

$166.61M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.6

Enterprise value

$65.06M

?
Relative Growth: Rel. Growth: 32
Relative Strength: Rel. Strength: 2
Relative Valuation: Rel. Valuation: 18
Relative Profitability: Rel. Profitability: 32

ADC Therapeutics is a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), transforming treatment for patients through our focused portfolio with ZYNLONTA® (loncastuximab tesirine-lpyl). ADC ...

Highlights
Adc Therapeutics's EPS has surged by 61% YoY and by 39% QoQ
The company's net income rose by 43% YoY and by 29% QoQ
Adc Therapeutics's quick ratio has decreased by 36% YoY and by 26% from the previous quarter
Adc Therapeutics's equity has decreased by 15% YoY and by 5% from the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://www.adctherapeutics.com
Peers: OLMA OMER VIVS ORIC

Key stats

What are the main financial stats of ADCT

ADCT stock price

How has the Adc Therapeutics stock price performed over time
Intraday
-1.14%
1 week
16.52%
1 month
24.29%
1 year
-60.33%
YTD
-63.03%
QTD
21.96%

Financial performance

How have Adc Therapeutics's revenue and profit performed over time
Revenue
$79.58M
Gross profit
$70.72M
Operating income
-$99.55M
Net income
-$96.91M
Gross margin
88.9%
Net margin
-121.8%
Adc Therapeutics's net margin has increased by 45% YoY and by 30% QoQ
The company's net income rose by 43% YoY and by 29% QoQ
ADCT's operating margin is up by 31% year-on-year and by 16% since the previous quarter
Adc Therapeutics's operating income has increased by 29% YoY and by 16% QoQ

Price vs fundamentals

How does ADCT's price correlate with its fundamentals

Growth

What is Adc Therapeutics's growth rate over time

Valuation

What is Adc Therapeutics stock price valuation
P/E
N/A
P/B
N/A
P/S
2.54
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
0.82
Adc Therapeutics's EPS has surged by 61% YoY and by 39% QoQ
Adc Therapeutics's equity has decreased by 15% YoY and by 5% from the previous quarter
ADCT's price to sales (P/S) is 79% lower than its 5-year quarterly average of 12.2 and 53% lower than its last 4 quarters average of 5.5
The revenue has increased by 3% YoY

Efficiency

How efficient is Adc Therapeutics business performance
Adc Therapeutics's return on sales has surged by 63% YoY and by 47% QoQ
The return on invested capital has surged by 55% year-on-year and by 44% since the previous quarter
The ROA has grown by 39% YoY and by 27% from the previous quarter

Dividends

What is ADCT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ADCT.

Financial health

How did Adc Therapeutics financials performed over time
Adc Therapeutics's total assets is 45% less than its total liabilities
ADCT's current ratio is down by 39% year-on-year and by 26% since the previous quarter
Adc Therapeutics's quick ratio has decreased by 36% YoY and by 26% from the previous quarter
Adc Therapeutics's debt is 152% higher than its equity
Adc Therapeutics's equity has decreased by 15% YoY and by 5% from the previous quarter
The debt to equity has grown by 10% YoY and by 3.7% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.